Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.5600
-0.0365 (-6.12%)
Jul 25, 2025, 1:34 PM - Market open

Company Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.

In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.

The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.

Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Plus Therapeutics, Inc.
Plus Therapeutics logo
CountryUnited States
Founded1996
IndustryBiotechnology
SectorHealthcare
Employees21
CEOMarc Hedrick

Contact Details

Address:
2710 Reed Road, Suite 160
Houston, Texas 77051
United States
Phone737 255 7194
Websiteplustherapeutics.com

Stock Details

Ticker SymbolPSTV
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001095981
CUSIP Number72941H400
ISIN NumberUS72941H5090
Employer ID33-0827593
SIC Code3841

Key Executives

NamePosition
Dr. Marc H. Hedrick M.B.A., M.D.President, Chief Executive Officer and Director
Andrew J. Sims CPAVice President of Finance and Chief Financial Officer
Dr. Michael Stanley Rosol Ph.D.Chief Development Officer
Desiree SmithCorporate Controller
Russell W. BradleyPresident and GM of CNSide Diagnostics

Latest SEC Filings

DateTypeTitle
Jul 21, 2025ARSFiling
Jul 21, 2025DEF 14AOther definitive proxy statements
Jul 18, 20258-KCurrent Report
Jul 11, 2025PRE 14AOther preliminary proxy statements
Jun 25, 2025SCHEDULE 13G/AFiling
Jun 23, 2025EFFECTNotice of Effectiveness
Jun 23, 2025RWFiling
Jun 23, 2025424B3Prospectus
Jun 20, 20258-KCurrent Report
Jun 20, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933